SINSIN PHARMACEUTICAL (002800) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, SINSIN PHARMACEUTICAL (002800) reported revenue of 113.8 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025113.8 billion KRW10.8 billion KRW9.3 billion KRW[source]
2024106.4 billion KRW6.9 billion KRW4.8 billion KRW[source]
2023102.6 billion KRW6.0 billion KRW4.6 billion KRW[source]
202291.9 billion KRW5.4 billion KRW4.4 billion KRW[source]
202174.0 billion KRW-1.3 billion KRW-1.4 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025137.4 billion KRW62.4 billion KRW75.0 billion KRW[source]
2024129.5 billion KRW63.2 billion KRW66.3 billion KRW[source]
2023124.3 billion KRW61.7 billion KRW62.6 billion KRW[source]
2022121.1 billion KRW61.0 billion KRW60.1 billion KRW[source]
2021114.1 billion KRW58.9 billion KRW55.1 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
20258.6 billion KRW-2.3 billion KRW-2.9 billion KRW[source]
20245.9 billion KRW-5.6 billion KRW-208 million KRW[source]
20233.9 billion KRW-6.1 billion KRW226 million KRW[source]
20225.5 billion KRW-1.1 billion KRW-2.8 billion KRW[source]
202123 million KRW-2.7 billion KRW925 million KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice